Company Profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Latest News

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

Reasons to Hold Veeva Systems Stock in Your Portfolio for Now

Veracyte (VCYT) Stock Still Looks Cheap As Its 107% Run Continues

Is it the Right Time to Add Phibro Stock to Your Portfolio?

Smith+Nephew Launches CARTIHEAL Implant Across Key European Markets

Bruker Gains 66.3% in a Year: What's Driving the Rally?
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data